The ownership structure of Immunic, Inc. is heavily concentrated among specialized institutional investment funds, healthcare venture capital firms, and professional asset management corporations. Prominent institutional stakeholders holding significant percentage blocks of common stock include Aberdeen Asset Management, BVF Partners, Millennium Management, Avidity Partners Management, and Braidwell LP, alongside various other specialized biotech funds. These institutional entities control the vast majority of the company's outstanding equity, while corporate insiders and executive officers hold smaller, aligned ownership percentages designed to support the firm's clinical drug development pipelines.